HomeCompareAIQUY vs PFE

AIQUY vs PFE: Dividend Comparison 2026

AIQUY yields 1.75% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $15.6K in total portfolio value· pulled ahead in Year 10
10 years
AIQUY
AIQUY
● Live price
1.75%
Share price
$41.50
Annual div
$0.73
5Y div CAGR
29.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.0K
Annual income
$3,492.07
Full AIQUY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AIQUY vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIQUYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIQUY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIQUY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIQUY
Annual income on $10K today (after 15% tax)
$148.84/yr
After 10yr DRIP, annual income (after tax)
$2,968.26/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $19,351.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIQUY + PFE for your $10,000?

AIQUY: 50%PFE: 50%
100% PFE50/50100% AIQUY
Portfolio after 10yr
$41.8K
Annual income
$14,875.40/yr
Blended yield
35.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AIQUY
Analyst Ratings
4
Buy
1
Sell
Consensus: Buy
Altman Z
4.8
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIQUY buys
0
PFE buys
0
No recent congressional trades found for AIQUY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIQUYPFE
Forward yield1.75%6.13%
Annual dividend / share$0.73$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.1%13.2%
Portfolio after 10y$34.0K$49.6K
Annual income after 10y$3,492.07$26,258.71
Total dividends collected$12.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: AIQUY vs PFE ($10,000, DRIP)

YearAIQUY PortfolioAIQUY Income/yrPFE PortfolioPFE Income/yrGap
1$10,926$226.06$9,153$693.39+$1.8KAIQUY
2$11,989$298.01$8,593$849.25+$3.4KAIQUY
3$13,223$394.53$8,336$1,066.78+$4.9KAIQUY
4$14,673$525.01$8,437$1,384.80+$6.2KAIQUY
5$16,403$702.94$9,013$1,875.40+$7.4KAIQUY
6$18,500$948.12$10,306$2,680.72+$8.2KAIQUY
7$21,085$1,290.15$12,820$4,101.38+$8.3KAIQUY
8$24,335$1,774.14$17,673$6,826.70+$6.7KAIQUY
9$28,509$2,470.53$27,543$12,591.86+$966.00AIQUY
10← crossover$33,997$3,492.07$49,560$26,258.71$15.6KPFE

AIQUY vs PFE: Complete Analysis 2026

AIQUYStock

L'Air Liquide S.A. provides gases, technologies, and services for the industrial and health sectors in Europe, the Americas, the Asia Pacific, the Middle East, and Africa. The company's Gas & Services segment offers oxygen, nitrogen, argon, hydrogen, and carbon monoxide to the metals, chemicals, refining, and energy sectors; and gases, application equipment, and associated services to the materials and energy, automotive and manufacturing, food and pharmaceuticals, technology and research, and craftsmen and retail sectors. It also supplies medical gases, hygiene products, equipment, and services to hospitals, as well as to patients in their homes; and produces and distributes healthcare specialty ingredients for the cosmetics, pharmaceutical, and vaccine markets. In addition, this segment supplies gases, materials, and services for use in the production of semi-conductors, as well as flat screens and photovoltaic panels. Its Engineering & Construction segment designs, develops, and builds industrial gas production plants for third parties; and designs and manufactures plants in the traditional, renewable, and alternative energy sectors. The company's Global Markets & Technologies segment delivers technological solutions, such as molecules, equipment, and services to support the markets of energy transition, primarily in transport, energy, and waste valorization, as well as related to deep tech in the space exploration, aerospace, and big science. This segment also invests in biomethane production units, as well as develops stations for distributing natural bio-gas for vehicles and hydrogen to support clean mobility; operates biomethane production units for use in the maritime industry; and supplies gases for the offshore oil and gas platforms, offshore wind turbines, and cryogenic transportation by sea. L'Air Liquide S.A. was incorporated in 1902 and is headquartered in Paris, France.

Full AIQUY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AIQUY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIQUY vs SCHDAIQUY vs JEPIAIQUY vs OAIQUY vs KOAIQUY vs MAINAIQUY vs JNJAIQUY vs MRKAIQUY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.